To study the effects of excision repair cross-complementing 1 (ERCC1) on the pathophysiological process of brain ischemia, we examined the changes in ERCC1 expression, as well as the functional significance of ERCC1 in the rat brain following middle cerebral artery occlusion (MCAO). The results were as follows: (1) ERCC1 immunopositive cells were widely distributed in various brain regions. ERCC1 expression was localized to the nuclei of neurons and astrocytes. (2) ERCC1 expression, as determined by western blot, increased at 3 days, remaining until 14 days, in the ipsilateral cortex and striatum following MCAO. Immunohistochemical analysis demonstrated that ischemia induced increased ERCC1 expression within the periinfarct core, with increasingly less expression toward the core. (3) Knockdown of ERCC1 expression by intraventricular injection of antisense plasmids increased DNA damage and infarct volume in the ischemic brain. (4) ERCC1 overproduction, by injection of expression plasmids, significantly reduced infarct volume and the accumulation of DNA-damaged neurons. Taken together, these results indicate that both endogenous ERCC1 and exogenous ERCC1 have an important neuroprotective function in the brain. In addition, administration of ERCC1 to the brain could prove to be a successful strategy for neuronal protection against ischemic injury.
Introduction
Brain ischemia induces the release of excessive reactive oxygen and nitrogen species, resulting in DNA damage comprising base modifications, DNA single-strand breaks (SSB) and DNA double-strand breaks (DSB). [1] [2] [3] The accumulation of damaged DNA lesions results in cell death, due to various induced intracellular signaling pathways. [4] [5] [6] In addition, brain ischemia induces specific expression of genes related to the DNA repair pathway. Proliferating cell nuclear antigen (PCNA), which is required for DNA synthesis and nucleotide excision repair (NER), is upregulated in the CA3/dentate gyrus and downregulated in the vulnerable CA1 region following global ischemia. PCNA is also upregulated in the peri-core zones following short periods of middle cerebral artery occlusion (MCAO; 30 or 60 min). 7, 8 Short MCAO periods (30 or 60 min) markedly induce longlasting base excision repair (BER) activity by upregulating expression and activity of essential BER enzymes. [9] [10] [11] Short periods of global ischemia induce neuronal expression of Ku70/80, which are also involved in repair of DSB. 12 The neuroprotective effects of antioxidants, growth factors and ischemic preconditioning (IP) on cerebral ischemia are partly related to enhanced endogenous DNA repair due to increased expression and activity of DNA repair factors. Melatonin has been shown to upregulate excision repair cross-complementing group 6 (ERCC6) mRNA expression in the peri-ischemic region of rat brains. 13 Vascular endothelial growth factor antisense treatment resulted in increased infarct volume and decreased ischemia-induced ERCC6 expression in the rat brain. 14, 15 Moreover, IP markedly increased BER activity, whereas simultaneously reducing the nuclear accumulation of several oxidative DNA lesions following subsequent severe ischemia. 9, 16 Thus the accumulation and repair of DNA damage is an important contributing factor in ischemic neuronal death and survival.
NER is one of the most important DNA repair pathways and is critical in repairing various DNA lesions. 17 The active cellular process of NER requires a concerted effort of more than 25 polypeptides, comprising Xeroderma pigmentosum group A-G, Cockayne syndrome A-B, replication protein A and transcription factor IIH. The cerebella of mice lacking both the xpa and csb genes are hypoplastic, as well as exhibit impaired foliation and stunted Purkinje cell dendrites, which suggests that NER is indispensable in the mammalian central nervous system. 18 ERCC1 is essential for NER, and interacts with XPF to make a 5 0 incision to the lesion site. 19, 20 Hamilton and colleagues 21, 22 have demonstrated that complementation of ERCC1 and XPF proteins in cell-free extracts of cisplatin-sensitive cells resulted in increased repair activity, as well as reduced ERCC1 with full-length antisense perturbed NER, proving that ERCC1 is a rate-limiting component of NER. ERCC1 is also involved in DSB repair 23, 24 and interstrand cross-link repair, 25 as well as homologous 26, 27 and class switch recombination. 28 Moreover, an elevated level of 8-hydroxyl-2 0 -deoxyguanosine damage was observed in ERCC1-deficient mice, which could be ameliorated by ERCC1 transgene. 29 Accordingly, it has been speculated that ERCC1 is an essential DNA repair enzyme in the brain.
Because of the function of ERCC1 in DNA repair, we asked whether ERCC1 could alleviate DNA damage following ischemia, and/or protect the brain against ischemic injury. A rat MCAO model was used to induce transient focal brain ischemia, and expression of ERCC1 was analyzed in the brain. Knockdown and overexpression of ERCC1 in the ischemic brain revealed that both endogenous and exogenous ERCC1 could protect the brain against ischemic injury.
Results

Induction of ERCC1 in the rat brain following transient MCA occlusion
The expression of ERCC1 in ischemic and sham-operated rat brains was first assessed by western blot. ERCC1 proteins were observed at low levels in the striatum and cortex of sham-operated rats (Figure 1 ). However, transient MCAO, in a time-dependent manner, induced changes in ERCC1 expression in both regions. Protein levels significantly increased at 3 days, and persisted to 14 days, following MCAO (Po0.05; Figure 1 ).
Immunohistochemical analysis indicated that ERCC1-positive cells were detected in the medial striatum (MS) and frontoparietal cortex (FPC), which are the salvageable tissues 2 ( Figure 2d , e, j and k), but not in lateral striatum (LS) and parietal cortex (PC), which are the irreversible damaged core (Figure 2g , h, m and n). The densities of immunopositive cells increased at 14 days after ischemia in the MS (952±117 vs 568±21 cells per mm 2 in the sham group, Po0.05; Figure 2b ) and FPC (1354±22 vs 976±79 cells per mm 2 , Po0.01; Figure 2b ), which paralleled to the results of western blot analysis. Further, highly magnified photomicrographs showed the ERCC1-positive staining was mainly localized to the nucleus (Figure 2 ,insets) . Double immunostaining showed that ERCC1-positive cell co-stained with microtubule-associated protein-2 (MAP-2), a specific neuronal marker, or with glial fibrillary acidic protein (GFAP), an astrocytic marker, suggesting that ERCC1 is mainly located in the nuclei of both neurons and astrocytes ( Figure 3 ).
Deterioration of ischemia-induced DNA damage and infarct of rat brain by ERCC1 knockdown
To assess the function of endogenous ERCC1 in ischemic injury, we selectively reduced the expression of ERCC1 in ischemic rat brain using antisense technique. Various doses (1, 2.5, 5 and 10 mg) of pcDNA3-ERCC1-antisense (ERCC1 antisense) plasmid were injected into lateral ventricle of rat brain after MCAO. At 3 days after ischemia, protein extracts from ipsilateral cortex were immunoblotted for ERCC1 and b-actin. ERCC1 antisense treatments at the doses of 5 and 10 mg resulted in a significant reduction of ERCC1 protein level compared with pcDNA3 (control plasmid) group (Po0.05; Figure  4a and b). On the basis of the dose-response effect, we injected 5 mg of ERCC1 antisense plasmids or pcDNA3 plasmids into lateral ventricle of rats after ischemia and observed the expression of ERCC1 at different time 
Amelioration of ischemia-induced DNA damage and infarct of rat brain by ERCC1 overexpression
To further observe the effects of exogenous ERCC1 on the pathophysiological process of brain ischemia, we injected ERCC1-EGFP-N1 (ERCC1) or pEGFP-N1 (enhanced green fluorescent protein (EGFP), control) into the rat lateral ventricle following ischemia. Western blot analysis, using an ERCC1-specific antibody, revealed expression of ERCC1-EGFP fusion protein in the rat brains as indicated (Figure 6i ). Immunohistochemical staining of EGFP, a reporter protein, confirmed exogen- Relative ratio (ERCC1/b-actin) was normalized to the control (pcDNA3 plasmid). Values in b and d represent mean ± s.e.m., and were analyzed by one-way analysis of variance (ANOVA), followed by Student's t-test (*Po0.05 vs controls, n ¼ 4 per group). Figure 5 Increased number of DNA-damaged cells and infarct volume followed by excision repair cross-complementing 1 (ERCC1) antisense treatment in the ischemic brain. DNA polymerase I-mediated digoxigenin-dUTP nick-translation (PUNT) labeling was used to detect DNA-damaged cells in the rat brain following injections of ERCC1 antisense/pcDNA3 (a-d). Panels c and d are high-power magnifications of boxes in a and b, respectively. The infarct area (encircled with dotted line) was determined by Fluoro-Jade B staining (f, g). ERCC1 antisense treatment significantly increased the number of PUNT-positive cells (e) and infarct volume (h) at 7 days of reperfusion after middle cerebral artery occlusion (MCAO). Data in e and h represent mean±s.e.m., and were analyzed by independent-sample t-tests (*Po0.05 vs controls, n ¼ 8 per group). Figure  6g and h) were then used to reveal DNA damage and neuronal injury in the ischemic rat brains, respectively. Results demonstrated that ERCC1 overexpression dramatically decreased the number of DNA-damaged neurons (Po0.05; Figure 6j ) and reduced ischemic infarct volume (Po0.05; Figure 6k ) in the ipsilateral hemisphere, compared to the control animals.
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Discussion
The present study provides the first evidence that ERCC1 has a protective role in the pathophysiological process of ischemic injury following transient MCAO in the rat brain. Results demonstrated that ischemia induced increased ERCC1 protein expression in the rat brain. Reduced endogenous ERCC1 levels, produced by specific antisense, increased DNA damage accumulation and ischemic brain damage. In contrast, ERCC1 overexpression significantly reduced DNA damage and infarct volume. Taken together, these results revealed that both endogenous and exogenous ERCC1 are capable of protecting neurons against ischemic injury in the rat brain.
NER in human cells comprises various highly coordinated steps executed by perhaps 30 distinct proteins that recognize DNA damage, incise the lesion, and resynthesize and ligate the repair patch. 19 Among them, ERCC1 has been demonstrated to be a rate-limiting component of NER, in particular in tumor cells. In the present study, we determined that NER is also involved in the pathophysiological process of the brain following stroke. For example, ERCC1 expression, an important factor of NER components, could be time dependently induced in the ischemic region of brains (Figure 1) . Morphologically, ERCC1 protein was detected in the ischemic penumbra (Figure 2) , where the tissue has the potential to be rescued after ischemia. However, the protein was not expressed in the ischemic core, where cells were irreversibly damaged. Quantitative analysis also revealed that ERCC1-positive cell density in the ischemic penumbra significantly increased 14 days after MCAO. Meanwhile, ERCC1 expression in neurons and astrocytes, as demonstrated by immunohistochemical double staining of ERCC1 and MAP-2, a neuronal marker, or GFAP, an astrocytic marker (Figure 3) . Collectively, the present results suggest that ERCC1 might be involved in DNA repair of neuronal cells in mammalian brains following stroke.
Next, the functional significance of ERCC1 expression was analyzed by altering ERCC1 brain expression using intraventricular injections of ERCC1-expressing orantisense plasmids. Plasmids were combined with cationic lipofectamine to effectively and logically modulate ERCC1 expression levels in the ischemic brain, further demonstrating that liposome-mediated plasmid transfection is a useful technique for introducing target protein expression in traumatic 30 and ischemic injured brains. 31, 32 Results from the present study also further confirmed that in vivo transfection of full-length ERCC1 antisense plasmids could effectively knock down ERCC1 protein expression. 22 For example, preinjection with ERCC1 antisense plasmids into the lateral ventricle resulted in time-and dose-dependent reduction of ERCC1 expression in the brain ischemic regions following stroke (Figure 4) . Moreover, knockdown of ERCC1 expression resulted in more severe DNA and neuronal damage in the ischemic rat brains ( Figure 5 ). This result clearly suggests that upregulation of endogenous ERCC1 expression in the brain following stroke could be an important compensatory response to ischemic injury, thereby assisting neurons to repair damaged DNA. If this were true, enhanced ERCC1 expression should increase DNA repair activity and reduce the amount of damaged DNA in the ischemic injured brain. Therefore, ERCC1-expressing plasmids were administered into the lateral ventricle to induce an overproduction of target protein in the rat brain. With this model, we determined that ERCC1 overexpression decreased the number of DNAdamaged cells and diminished the ischemic infarct volume ( Figure 6 ). Collectively, both endogenous ERCC1 protein expression and exogenous ERCC1 protein expression protect the brain against ischemic injury. It should be noted that the present study only modulated the levels of ERCC1, a factor of the NER components, which dramatically altered the number of DNAdamaged cells and ischemic infarct volume. These results clearly support the hypothesis that NER participates in neuronal DNA repair, and that ERCC1 is one of the most important components of NER in the brain. Previous studies have demonstrated that increased levels of DNA repair factors can directly contribute to enhanced endogenous DNA repair activity and neuroprotective effects. 9, 16 Combined with the present observations, one could speculate that improved DNA repair functions, by elevated DNA repair factor levels and bioactivity, should be capable of preventing accumulation of damaged DNA, thereby reducing ischemic neuronal death. Taken together, these results suggest that upregulation of ERCC1 expression in the brain could provide a novel gene therapeutic strategy for neuroprotection following ischemic injury.
Materials and methods
Materials
Lipofectamine 2000 reagent was purchased from Invitrogen (Carlsbad, CA, USA). Protease inhibitor cocktail tablets, PUNT staining kit, nitroblue tetrazolium (NBT) and 5-bromo-4-chloro-5-indolyl phosphate (BCIP) were all purchased from Roche Molecular Biochemicals (Mannheim, Germany). Polyvinylidene fluoride membrane (PVDF) was purchased from Bio-Rad (Hercules, CA, USA). Diaminobenzidine (DAB) and mouse monoclonal anti-b-actin were purchased from Sigma (St Louis, MO, USA). Fluoro-Jade B, rabbit polyclonal anti-MAP-2 and rabbit polyclonal anti-GFAP were purchased from Chemicon (Temecula, CA, USA). Mouse monoclonal anti-EGFP, rabbit polyclonal anti-ERCC1 and Western Blotting Luminol Reagent were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Mouse monoclonal anti-ERCC1 was purchased from NeoMarkers (Fremont, CA, USA). ABC-alkaline phosphatase kit ERCC1 protects against brain ischemic injury K-Y He et al (anti-mouse and rabbit IgG), ABC peroxidase kits (antimouse and rabbit IgG) and Vector Blue were purchased from Vector Laboratories Inc. (Burlingame, CA, USA).
Transient middle cerebral artery occlusion
Male, Sprague-Dawley rats (Shanghai Experimental Animal Center, Chinese Academy of Sciences), weighing 220-250 g each, were anesthetized with 10% chloral hydrate (360 mg kg À1 , i.p.). During all procedures, body temperature was monitored by a rectal probe and maintained at 37 ± 0.5 1C using a heating pad and an overhead lamp. Arterial blood samples were collected to measure pH, PO 2 and PCO 2 with an AVL 990 Blood Gas System. Rats maintained within the physiological range (pH, 7.32 ± 0.005; PO2, 86.04 ± 1.21 mm Hg and PCO2, 49.24±1.13 mm Hg) were subjected to surgery. The middle cerebral artery was occluded with a 4-0 nylon suture for 30 min, according to previously described methods. 14, 33 On the following day after surgery, each animal was subjected to an assessment of neurological deficit scores, as previously described. 33 Rats with neurological deficits were used for further experiments. All efforts were made to minimize animal suffering and to reduce the number of animals used. The Medical Experimental Animal Administrative Committee of Shanghai approved all animal experiments.
Plasmid administration
The cDNA fragment encoding for human ercc1 was reversely and directly inserted into the pcDNA3 vector and pEGFP-N1 vector, respectively. Following MCAO, rats were divided into ERCC1 antisense (pcDNA3-ERCC1-antisense plasmid) and ERCC1 overexpression (pERCC1-EGFP-N1 plasmid) groups using pcDNA3 and pEGFP-N1 plasmids as controls. The plasmid mixture (3 ml total, including 1 ml plasmids, 1 ml 0.9% sodium chloride and 1 ml Lipofectamine 2000) was stereotaxically delivered into the ipsilateral lateral ventricle following reperfusion (bregma coordinates: AP À0.8 mm, ML 1.4 mm and DV À3.6 mm from the pial surface). 34 For ERCC1 antisense treatment, rats were injected with the plasmids at doses of 1, 2.5, 5 and 10 mg. For ERCC1 overexpression in the brain, 10 mg of overexpressing plasmid was injected into the lateral ventricle. Following recovery from anesthesia, rats were returned to their cages and allowed free access to food and water. The animals were killed at the indicated times shown in figures.
Western blot analysis
To determine the time course of ERCC1 expression in the brain following ischemia, with/without antisense treatment, rats (n ¼ 3 or 4) were decapitated under deep anesthesia at the desired time points after surgery (as indicated in Figures 1 and 3 ) . Ipsilateral striatal and cortical tissues were quickly dissected on ice, frozen in dry ice and maintained at -80 1C for further analysis.
To identify the effect of the ERCC1-expressing plasmid, we transfected pERCC1-EGFP-N1 or pEGFP-N1 plasmids either into cultured PC12 cells or the rat brain using Lipofectamine 2000, according to the manufacturer's instructions. At 24 h after transfection, PC12 cells were harvested for western blot analysis to identify expression of ERCC1. In the rat brain (n ¼ 5), the ipsilateral striatum to MCAO was collected 3 days after lateral ventricle injection with plasmids, and maintained at -80 1C for further analysis.
The frozen samples or cells were homogenized in lysis buffer (50 mM Tris-HCl (pH 7.5), containing 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 1 Â proteinase inhibitor cocktail), incubated on ice for 30 min and then centrifuged at 12 000 g for 30 min at 4 1C. The supernatants were collected, and protein concentration was determined.
Protein (50 mg) from each sample was electrophoresed on a 12% SDS-polyacrylamide gel, and subsequently transferred to PVDF membrane. The membrane was blocked by 5% non-fat milk, and incubated with a rabbit polyclonal antibody against ERCC1 (1:1000) overnight at 4 1C, followed by incubation with horseradish-peroxidase-conjugated goat anti-rabbit IgG (1:3000) for 1 h at room temperature. Peroxidase activity was visualized by a western blot luminol reagent system. Normalization was performed by stripping films and reprobing for b-actin. Omission of the primary antibody served as the control for nonspecific binding. Films were scanned and subsequently analyzed by measuring optical densities of immunostained bands, using ImageJ 1.37 (NIH, Bethesda, MD, USA). For each brain region, the value ratios obtained from the ischemic and control animals were averaged from at least three different animals at each time point.
ERCC1 and EGFP immunohistochemical study
Rats were anesthetized with 10% chloral hydrate and intracardially perfused with 0.9% saline solution, followed by 250 ml 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) at the desired time points following surgery. The brains were removed, and 30-mm thick coronal serial sections were cut on a freezing microtome (Jung Histocut, model 820-II; Leica, Wetzlar, Germany) at the bregma level from 1.60 to À4.80 mm, as previously described, 34 and stored at À20 1C in a cryoprotectant solution.
Free-floating sections were used for immunostaining as previously described. 32 The sections were incubated with mouse monoclonal antibody against ERCC1 or mouse monoclonal antibody against EGFP (1:100) at 4 1C overnight, followed by biotinylated anti-mouse secondary antibody (1:200) for 45 min and avidin-biotinperoxidase (1:200) for 30 min. The peroxidase reaction was detected with 0.05% DAB in 0.1 M phosphate buffer and 0.01% H 2 O 2 . Adjacent sections received identical treatment, with the exception of primary antibody incubation, and served as negative controls; these sections displayed no specific staining.
Immunohistochemical double staining
To investigate the cell types of ERCC1-positive cells, we performed immunohistochemical double staining using antibodies specific to ERCC1 and MAP-2 or GFAP. The sections were first incubated with anti-ERCC1 antibody, as described above. However, avidin-biotin peroxidase was replaced by avidin-biotin-conjugated alkaline phosphatase, and reactive signals were revealed with Vector Blue (blue color) for the ERCC1-GFAP double staining. Subsequently, the sections were treated with rabbit polyclonal antibody against MAP-2 or GFAP (1:200) overnight at 4 1C, followed by incubation with biotinylated secondary antibodies and avidin-biotin-alkaline In situ detection of DNA single-strand breaks PUNT labeling was used to detect DNA SSB in freefloating sections. Briefly, sections were incubated in a moist-air chamber for 2 h at 37 1C with a reaction mixture containing 5 mM MgCl 2 , 10 mM 2-mercaptoethanol, 20 mg ml À1 bovine serum albumin, dGTP, dCTP and dTTP, at 30 mM each, and 20 mM dATP, 10 mM digoxigenindUTP and 40 U ml À1 Escherichia coli DNA polymerase I in 0.1 M Tris-HCl (pH 7.4). Reactions were terminated by washing with 0.1 M Tris-HCl containing 2% normal goat serum, sections were incubated in alkaline phosphataselabeled anti-digoxigenin antibody (1:1000) at 24 1C for 3 h, followed by incubation with alkaline phosphate substrate solution containing NBT and BCIP at 24 1C for 1 h in the dark for color development, and mounted on gelatinized glass slides. To determine nonspecific labeling, we incubated sections in reaction mixture lacking DNA polymerase I.
Fluoro-Jade B staining and measurement of infarct volume
Animals (n ¼ 8) were killed at 7 days after MCAO, and 30-mm thick coronal brain sections were serially cut at 390-mm intervals from frozen brains using a microtome. The sections were stained with Fluoro-Jade B to identify degenerating neurons, as previously described. 35 FluoroJade B staining signals were detected at an excitation of 480 nm and an emission of 525 nm under an epifluorescence microscope with a Â 5 objective, and captured with a SPOT-RT 3-chip digital camera (Diagnostic Instruments Inc., Sterling Heights, MI, USA). The infarct volume was calculated using an image processing and analysis system (Q570IW; Leica). To exclude the effects of varied brain size on infarct volume, the percentage of infarct volume in the contralateral hemisphere was used to express the degree of brain damage, as previously reported. 36 Data quantification and statistical evaluation ERCC1-positive cells were stereologically counted in a single 30-mm section (approximately +0.70 mm from bregma) per rat, using Stereo Investigator software (Microbrightfield, Williston, VT, USA) under a light microscope. The density of ERCC1-positive cells was reported as mean ± s.e.m. per mm 2 . To determine the number of PUNT-positive cells, every six random images from the striatum and cortex were captured using a microscope with a Â 20 objective. The number of cells was counted using ImageJ 1.37 software (NIH). Western blot analyses were repeated in triplicate, and data were reported as mean±s.e.m. Multiple group comparisons were performed by one-way analysis of variance (ANOVA), followed by Student's t-test. Comparison between two experimental groups was made using the unpaired Student's t-test. Po0.05 was considered statistically significant.
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